Citadel Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.77M | Buy |
294,157
+258,009
| +714% | +$7.56M | ﹤0.01% | 3623 |
|
|
2025
Q4 | $1.05M | Buy |
+36,148
| New | +$1.08M | ﹤0.01% | 7300 |
|
|
2025
Q3 | – | Sell |
-381,389
| Closed | -$9.64M | – | 12708 |
|
|
2025
Q2 | $9.29M | Buy |
+381,389
| New | +$8.36M | ﹤0.01% | 3135 |
|
|
2025
Q1 | – | Sell |
-79,357
| Closed | -$1.99M | – | 14428 |
|
|
2024
Q4 | $1.87M | Buy |
79,357
+3,107
| +4% | +$76.5K | ﹤0.01% | 5771 |
|
|
2024
Q3 | $1.95M | Buy |
76,250
+64,124
| +529% | +$1.63M | ﹤0.01% | 5584 |
|
|
2024
Q2 | $285K | Sell |
12,126
-295,297
| -96% | -$7.45M | ﹤0.01% | 9247 |
|
|
2024
Q1 | $8.84M | Buy |
+307,423
| New | +$9.24M | ﹤0.01% | 3095 |
|
|
2023
Q4 | – | Sell |
-128,754
| Closed | -$3.5M | – | 14227 |
|
|
2023
Q3 | $3.59M | Sell |
128,754
-55,557
| -30% | -$1.82M | ﹤0.01% | 4180 |
|
|
2023
Q2 | $6.28M | Buy |
184,311
+135,327
| +276% | +$4.25M | ﹤0.01% | 3299 |
|
|
2023
Q1 | $1.47M | Sell |
48,984
-71,718
| -59% | -$2.22M | ﹤0.01% | 5948 |
|
|
2022
Q4 | $3.41M | Sell |
120,702
-287,014
| -70% | -$9.11M | ﹤0.01% | 4541 |
|
|
2022
Q3 | $13.4M | Sell |
407,716
-61,789
| -13% | -$2.27M | ﹤0.01% | 2361 |
|
|
2022
Q2 | $14.8M | Buy |
469,505
+436,404
| +1,318% | +$15.3M | ﹤0.01% | 2187 |
|
|
2022
Q1 | $1.52M | Buy |
+33,101
| New | +$1.58M | ﹤0.01% | 6705 |
|
|
2021
Q4 | – | Sell |
-306,859
| Closed | -$21.2M | – | 13747 |
|
|
2021
Q3 | $22.9M | Buy |
306,859
+221,243
| +258% | +$18.6M | ﹤0.01% | 1846 |
|
|
2021
Q2 | $7.92M | Buy |
85,616
+50,490
| +144% | +$4.29M | ﹤0.01% | 3515 |
|
|
2021
Q1 | $3.12M | Buy |
+35,126
| New | +$3.48M | ﹤0.01% | 5354 |
|
|
2020
Q4 | – | Sell |
-8,115
| Closed | -$647K | – | 10876 |
|
|
2020
Q3 | $517K | Buy |
+8,115
| New | +$476K | ﹤0.01% | 7251 |
|
|
2020
Q2 | – | Sell |
-20,794
| Closed | -$650K | – | 9731 |
|
|
2020
Q1 | $650K | Buy |
+20,794
| New | +$695K | ﹤0.01% | 6052 |
|
|
2019
Q4 | – | Sell |
-41,964
| Closed | -$1.24M | – | 9073 |
|
|
2019
Q3 | $1.24M | Buy |
41,964
+19,565
| +87% | +$636K | ﹤0.01% | 5222 |
|
|
2019
Q2 | $772K | Buy |
+22,399
| New | +$718K | ﹤0.01% | 6120 |
|
|
2019
Q1 | – | Sell |
-45,979
| Closed | -$1.1M | – | 9217 |
|
|
2018
Q4 | $1.1M | Buy |
+45,979
| New | +$1.3M | ﹤0.01% | 5164 |
|
|
2018
Q3 | – | Sell |
-34,445
| Closed | -$1M | – | 9172 |
|
|
2018
Q2 | $1M | Buy |
+34,445
| New | +$959K | ﹤0.01% | 5207 |
|
Other funds holding ARKG
Citadel Advisors's ARKG Position: Q1 2026 in Review
Citadel Advisors increased its ARK Genomic Revolution ETF (ARKG) stake by 714% in Q1 2026, buying an estimated $7.56M and bringing the position to 294,157 shares worth $7.77M. The position accounts for ﹤0.01% of the portfolio, ranked #3623.
Citadel Advisors first reported a position in ARKG in Q2 2018 and has held it in 23 quarters since. The position peaked at $22.9M in Q3 2021. 218 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.
- Citadel Advisors held 294,157 shares of ARK Genomic Revolution ETF worth $7.77M as of Q1 2026.
- Citadel Advisors bought 258,009 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $7.56M.
- ARK Genomic Revolution ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3623 holding.
- Citadel Advisors first reported a position in ARK Genomic Revolution ETF in Q2 2018 and has held it in 23 quarters since.
- Citadel Advisors's ARK Genomic Revolution ETF position peaked at $22.9M in Q3 2021.
- 218 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.